MX343087B - Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a. - Google Patents

Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.

Info

Publication number
MX343087B
MX343087B MX2015001391A MX2015001391A MX343087B MX 343087 B MX343087 B MX 343087B MX 2015001391 A MX2015001391 A MX 2015001391A MX 2015001391 A MX2015001391 A MX 2015001391A MX 343087 B MX343087 B MX 343087B
Authority
MX
Mexico
Prior art keywords
antibodies
isolation
purification
protein
affinity
Prior art date
Application number
MX2015001391A
Other languages
English (en)
Inventor
K Hickman Robert
Huang Qing
Perilli-Palmer Barbara
L Weed Cheryl
T Ennis Scott
Wan Min
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41835469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX343087B publication Critical patent/MX343087B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Abstract

La presente invención se refiere a un proceso para purificar adalimumab a partir de una cosecha de fermentación de un cultivo celular de ovario de hámster Chino (CHO) que expresa dicho adalimumab, dicho proceso comprende: a) unir adalimumab proveniente de dicha cosecha de fermentación a una resina de proteína A, b) eluir el adalimunab unido a un pH de elución de 3.6-4, y c) incubar el adalumumab eluído durante 1 a 3 horas.
MX2015001391A 2008-10-20 2011-04-19 Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a. MX343087B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19675308P 2008-10-20 2008-10-20

Publications (1)

Publication Number Publication Date
MX343087B true MX343087B (es) 2016-10-14

Family

ID=41835469

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2011004200A MX2011004200A (es) 2008-10-20 2009-10-20 Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
MX2018014395A MX2018014395A (es) 2008-10-20 2011-04-19 Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
MX2015001391A MX343087B (es) 2008-10-20 2011-04-19 Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2011004200A MX2011004200A (es) 2008-10-20 2009-10-20 Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
MX2018014395A MX2018014395A (es) 2008-10-20 2011-04-19 Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.

Country Status (18)

Country Link
US (5) US8895709B2 (es)
EP (2) EP2350127B1 (es)
JP (2) JP5808249B2 (es)
KR (1) KR20110091678A (es)
CN (2) CN105111309A (es)
AU (4) AU2009347206C1 (es)
BR (1) BRPI0920027A2 (es)
CA (3) CA2911256A1 (es)
ES (1) ES2535734T3 (es)
HK (1) HK1209428A1 (es)
IL (3) IL211918A (es)
MX (3) MX2011004200A (es)
NZ (1) NZ592095A (es)
RU (1) RU2520838C2 (es)
SG (1) SG10201702922VA (es)
TW (2) TW201024318A (es)
WO (1) WO2010141039A1 (es)
ZA (1) ZA201102523B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2703997C (en) 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
ES2535734T3 (es) * 2008-10-20 2015-05-14 Abbvie Inc. Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
BR112013008738B1 (pt) * 2010-10-11 2017-12-19 Abbvie Bahamas Ltd. Method for purification of a protein
BR112013013884A2 (pt) * 2010-12-06 2016-09-13 Pall Corp métodos de processamento contínuo para produtos biológicos
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2831572C (en) * 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2012160536A1 (en) * 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
EP2720768B1 (en) * 2011-06-08 2017-04-12 Agency For Science, Technology And Research Purification of biological products by constrained cohydration chromatography
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
BR112014012005A2 (pt) * 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2850099B1 (en) 2012-05-14 2017-01-18 Novo Nordisk A/S Stabilised protein solutions
US20140154270A1 (en) * 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
TW201348247A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150133643A1 (en) * 2012-06-06 2015-05-14 Emd Millipore Corporation Low Organic Extractable Depth Filter Media Processed with Solvent Extraction Method
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9890191B2 (en) 2012-09-03 2018-02-13 Kaneka Corporation Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
WO2014102814A1 (en) * 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2970375A1 (en) * 2013-03-14 2016-01-20 AbbVie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP3907233A1 (en) * 2013-05-15 2021-11-10 MedImmune Limited Purification of recombinantly produced polypeptides
KR101569783B1 (ko) * 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
CA2910770C (en) 2013-07-12 2018-02-27 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
EP3048109A4 (en) * 2013-09-17 2017-04-19 Kaneka Corporation Novel antibody purification method and antibody obtained therefrom, and novel antibody purification method using cation exchanger and antibody obtained therefrom
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2014370873B2 (en) * 2013-12-27 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
LT3116891T (lt) 2014-03-10 2020-03-25 Richter Gedeon Nyrt. Imunoglobulino gryninimas, naudojant išankstinio valymo pakopas
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
EP3145951A1 (en) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Methods of purifying antibodies
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
JP6630036B2 (ja) * 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
CN105566442A (zh) * 2014-10-11 2016-05-11 江苏泰康生物医药有限公司 一种降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化工艺
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3268100A1 (en) * 2015-03-13 2018-01-17 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
PL3334747T3 (pl) 2015-08-13 2024-04-02 Amgen Inc. Naładowana filtracja wgłębna białek wiążących antygen
CA2995385A1 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
SG11201807676UA (en) * 2016-04-01 2018-10-30 Ucb Biopharma Sprl Method for protein purification
AU2017251360A1 (en) * 2016-04-14 2018-11-01 Lonza Ltd Compositions and methods for the detection of host cell proteins
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EA201990317A1 (ru) 2016-08-16 2019-07-31 Ридженерон Фармасьютикалз, Инк. Способы определения количества индивидуальных антител из смеси
US10613063B2 (en) 2016-10-25 2020-04-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
JP2020500856A (ja) 2016-12-09 2020-01-16 グリックニック インコーポレイテッド 多価ｆｃ化合物を用いる炎症性疾患の治療方法
JP2020503855A (ja) * 2016-12-09 2020-02-06 グリックニック インコーポレイテッド 多量体化ストラドマーｇｌ−２０４５の製造最適化
EA201900326A1 (ru) 2016-12-23 2019-11-29 Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
WO2019036626A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
CN110997133A (zh) * 2017-08-23 2020-04-10 Jsr株式会社 色谱用载体、配体固定载体、色谱柱、靶物质的纯化方法和色谱用载体的制造方法
IL311002A (en) * 2017-12-21 2024-04-01 Genzyme Corp Methods for improved removal of impurities during protein A chromatography
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CN108239146A (zh) * 2018-03-26 2018-07-03 江苏中新医药有限公司 一种高纯度rhNGF的制备方法
US11225516B2 (en) * 2018-04-20 2022-01-18 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3843869A1 (en) * 2018-08-31 2021-07-07 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
KR20210096633A (ko) * 2018-11-29 2021-08-05 리폼 바이오로직스, 엘엘씨 단백질 처리를 위한 부형제 화합물
TW202112801A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
CN116547292A (zh) * 2020-10-02 2023-08-04 伊莱利利公司 用于减少抗体纯化过程中的宿主细胞蛋白质含量的方法和具有减少的宿主细胞蛋白质含量的抗体组合物
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113501857A (zh) * 2021-08-17 2021-10-15 沈阳百发科技有限公司 一种高活性重组蛋白的制备方法
WO2023141612A2 (en) * 2022-01-24 2023-07-27 University Of Florida Research Foundation, Incorporated Point of care testing system for antithrombin iii

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
JPS59156299A (ja) 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
PT802257E (pt) 1996-04-19 2003-01-31 Nestle Sa Linhagem imortalizada de celulas epiteliais do colon humano
AU5082698A (en) 1996-10-23 1998-05-15 Oravax, Inc Heat inactivation of viruses in antibody preparations
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
ATE425990T1 (de) 1996-11-27 2009-04-15 Genentech Inc Affinitatsreinigung von polypeptid-proteinen auf einer matrix
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
EP1075488B2 (en) 1998-05-06 2013-08-07 Genentech, Inc. Protein purification by ion exchange chromatography
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6586206B1 (en) 1999-09-27 2003-07-01 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
WO2001059089A2 (en) 2000-02-08 2001-08-16 Genentech, Inc. Improved galactosylation of recombinant glycoproteins
CA2800450A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
ATE398172T1 (de) 2001-05-11 2008-07-15 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
ATE421536T1 (de) 2001-06-05 2009-02-15 Genetics Inst Llc Verfahren zur reinigung stark anionischer proteine
KR20040054669A (ko) 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
DE60221553T2 (de) 2001-10-02 2008-04-10 Novo Nordisk Health Care Ag Verfahren zur herstelllung rekombinanter proteine in eukaryontischen zellen
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
CA2466881A1 (en) 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
ATE425989T1 (de) 2001-12-21 2009-04-15 Immunex Corp Proteinreinigungsverfahren
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
RU2304587C2 (ru) * 2002-06-10 2007-08-20 Гуд Байотек Копэрейшн СПОСОБ СЕЛЕКТИВНОГО ВЫДЕЛЕНИЯ АНТИТЕЛ IgY ИЗ ЯИЧНОГО ЖЕЛТКА ПТИЦ ОТРЯДА ГУСЕОБРАЗНЫХ (ВАРИАНТЫ)
JP4510938B2 (ja) 2002-07-15 2010-07-28 イミュネックス・コーポレーション 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地
KR20110027851A (ko) * 2002-07-19 2011-03-16 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
CA2499269A1 (en) * 2002-09-17 2004-04-01 Gtc Biotherapeutics, Inc. Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
WO2004104186A1 (en) 2003-05-15 2004-12-02 Wyeth Restricted glucose feed for animal cell culture
SI1648940T1 (sl) 2003-07-28 2016-08-31 Genentech, Inc. Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
PL2336172T3 (pl) 2003-10-27 2015-04-30 Wyeth Llc Usuwanie agregatów o dużej masie cząsteczkowej przy użyciu chromatografii hydroksyapatytowej
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
DE602005019038D1 (de) 2004-05-04 2010-03-11 Novo Nordisk Healthcare Ag O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
ES2634323T3 (es) 2004-09-30 2017-09-27 Bayer Healthcare Llc Dispositivos y procedimientos para la fabricación continua integrada de moléculas biológicas
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
ES2380485T3 (es) 2005-02-11 2012-05-14 Novo Nordisk Health Care Ag Producción de un polipéptido en un líquido de cultivo sin suero con hidrolizado de proteínas vegetales
US8067182B2 (en) 2005-03-11 2011-11-29 Wyeth Llc Method of weak partitioning chromatography
US8129508B2 (en) 2005-04-11 2012-03-06 Medarex, Inc. Protein purification using HCIC and ion exchange chromatography
US20090203055A1 (en) 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
CA2608818A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
ZA200710331B (en) 2005-06-17 2009-04-29 Elan Pharma Int Ltd Methods of purifying anti A Beta antibodies
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
PE20070796A1 (es) 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
MX2008014744A (es) 2006-05-19 2009-02-10 Glycofi Inc Composiciones de eritrocpoyetina.
JP2010510963A (ja) 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
WO2008007280A2 (en) 2006-06-28 2008-01-17 Koninklijke Philips Electronics N.V. Assay system and method
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
LT2061803T (lt) 2006-08-28 2019-11-25 Ares Trading Sa Fc turinčių baltymų gryninimo būdas
CA2661645C (en) 2006-09-08 2016-11-08 Wyeth Arginine wash in protein purification using affinity chromatography
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI548747B (zh) * 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
US10982250B2 (en) 2006-09-18 2021-04-20 Genentech, Inc. Methods of protein production
WO2008036899A2 (en) 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
WO2008068879A1 (en) 2006-12-06 2008-06-12 Jcr Pharmaceuticals Co., Ltd. Method for production of human erythropoietin
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
RU2518340C2 (ru) * 2007-03-30 2014-06-10 Эббви Инк Элементы рекомбинантного вектора экспрессии (reves) для усиления экспрессии рекомбинантных белков в клетках-хозяевах
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
CN101681396A (zh) 2007-04-16 2010-03-24 动量制药公司 限定的糖蛋白产品以及相关方法
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
US8053236B2 (en) 2007-05-11 2011-11-08 Amgen Inc. Feed media
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
CA2691692C (en) 2007-07-09 2021-05-18 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
RU2498991C2 (ru) 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
TWM332870U (en) * 2007-11-22 2008-05-21 Delta Electronics Inc Side-edge type backlight module
NZ585702A (en) 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
AU2009223054A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced ADCC function
US8772461B2 (en) 2008-04-15 2014-07-08 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
WO2010016943A2 (en) 2008-08-08 2010-02-11 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
KR101843915B1 (ko) 2008-08-14 2018-04-02 제넨테크, 인크. 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
US8025879B2 (en) 2008-09-26 2011-09-27 Eureka Therapeutics, Inc. Modified glycoproteins and uses thereof
ES2535734T3 (es) * 2008-10-20 2015-05-14 Abbvie Inc. Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A
RU2514657C2 (ru) 2008-10-20 2014-04-27 Эббви Инк, Способ получения препарата антитела против il-18 или его антигенсвязывающей части (варианты)
KR20110093799A (ko) 2008-10-20 2011-08-18 아보트 러보러터리즈 Ｉｌ-12에 결합하는 항체 및 이의 정제 방법
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
JP5793080B2 (ja) 2008-10-31 2015-10-14 ワイス・エルエルシー セラミックヒドロキシアパタイトクロマトグラフィーを使用する酸性タンパク質の精製
JP2012511531A (ja) 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
KR20110086184A (ko) 2008-12-22 2011-07-27 에프. 호프만-라 로슈 아게 면역글로불린 정제
WO2010080062A1 (en) 2009-01-08 2010-07-15 Ge Healthcare Bio-Sciences Ab Separation method using single polymer phase systems
JP5728392B2 (ja) 2009-03-05 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 免疫グロブリンの精製
JP5755136B2 (ja) 2009-03-27 2015-07-29 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法
US8063189B2 (en) 2009-04-13 2011-11-22 Bristol-Myers Squibb Company Protein purification by citrate precipitation
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
CA2763757A1 (en) 2009-05-28 2010-12-02 Boehringer Ingelheim International Gmbh Method for a rational cell culturing process
US20120277165A1 (en) 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
EP2451936B1 (en) 2009-07-06 2019-08-28 F.Hoffmann-La Roche Ag Method of culturing eukaryotic cells
MX2012000841A (es) 2009-07-24 2012-02-28 Hoffmann La Roche Optimizacion de la produccion de anticuerpos.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
JP2013501075A (ja) 2009-08-06 2013-01-10 ジェネンテック， インコーポレイテッド タンパク質精製におけるウイルス除去の改良方法
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
RU2564569C2 (ru) 2009-12-18 2015-10-10 Новартис Аг Промывочный раствор и способ промывки для аффинной хроматографии
WO2011087301A2 (ko) 2010-01-15 2011-07-21 성균관대학교산학협력단 기체 및 수분 차단용 그래핀 보호막, 이의 형성 방법 및 그의 용도
MX2012011556A (es) 2010-04-06 2013-02-21 Heliae Dev Llc Extraccion selectiva de proteinas de algas de agua adulce o agua salada.
EP2556163B1 (en) 2010-04-07 2016-08-10 Momenta Pharmaceuticals, Inc. Method for quantifying high mannose containing glycoforms
MX2012012526A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo celular mejorado.
PT2563906T (pt) 2010-04-26 2018-02-16 Novartis Ag Processo para cultivo de células cho
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
CN103080300B (zh) 2010-08-05 2015-11-25 安姆根有限公司 增加细胞培养物的产率和活力的二肽
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012040041A1 (en) * 2010-09-20 2012-03-29 Abbott Laboratories Purification of antibodies using simulated moving bed chromatography
BR112013008738B1 (pt) * 2010-10-11 2017-12-19 Abbvie Bahamas Ltd. Method for purification of a protein
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
WO2012078376A1 (en) 2010-12-08 2012-06-14 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
MX357821B (es) 2010-12-21 2018-07-25 Hoffmann La Roche Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
SG192632A1 (en) 2011-03-06 2013-09-30 Merck Serono Sa Low fucose cell lines and uses thereof
CN103582700B (zh) 2011-03-25 2016-08-17 弗·哈夫曼一拉罗切有限公司 新的蛋白质纯化方法
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012147048A2 (en) 2011-04-29 2012-11-01 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
JP6236383B2 (ja) 2011-05-13 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． トリスルフィド結合を防止および除去する方法
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
AU2012279230B2 (en) 2011-07-01 2016-08-18 Amgen Inc. Mammalian cell culture
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
EP2768845B1 (en) 2011-10-19 2017-01-18 Roche Glycart AG Separation method for fucosylated antibodies
WO2013158279A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Also Published As

Publication number Publication date
AU2009347206A1 (en) 2010-12-09
WO2010141039A1 (en) 2010-12-09
ES2535734T3 (es) 2015-05-14
IL211918A (en) 2016-03-31
TWI610936B (zh) 2018-01-11
TW201024318A (en) 2010-07-01
AU2015207915B2 (en) 2016-06-02
CN105111309A (zh) 2015-12-02
CA2738498A1 (en) 2010-12-09
AU2016222301A1 (en) 2016-09-15
AU2018203810A1 (en) 2018-06-21
EP2350127B1 (en) 2015-01-28
AU2009347206C1 (en) 2016-12-08
US20100135987A1 (en) 2010-06-03
EP2350127A1 (en) 2011-08-03
AU2015207915C1 (en) 2016-12-08
AU2009347206A8 (en) 2011-05-26
MX2011004200A (es) 2011-05-24
RU2011120191A (ru) 2012-11-27
US20150210735A1 (en) 2015-07-30
US9018361B2 (en) 2015-04-28
US20170158760A1 (en) 2017-06-08
US8895709B2 (en) 2014-11-25
AU2009347206B2 (en) 2015-08-20
US20160083452A1 (en) 2016-03-24
BRPI0920027A2 (pt) 2015-10-06
CN102257006A (zh) 2011-11-23
US20140255423A1 (en) 2014-09-11
SG10201702922VA (en) 2017-06-29
JP5808249B2 (ja) 2015-11-10
JP2012506383A (ja) 2012-03-15
HK1209428A1 (en) 2016-04-01
RU2520838C2 (ru) 2014-06-27
CA2932207A1 (en) 2010-12-09
IL211918A0 (en) 2011-06-30
EP2921501A1 (en) 2015-09-23
JP2015042645A (ja) 2015-03-05
IL232601A0 (en) 2014-06-30
IL244157A0 (en) 2016-04-21
TW201634476A (zh) 2016-10-01
AU2015207915A1 (en) 2015-08-20
ZA201102523B (en) 2011-12-28
MX2018014395A (es) 2020-07-29
NZ592095A (en) 2013-01-25
KR20110091678A (ko) 2011-08-12
CA2911256A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
AU2016222301A1 (en) Isolation and purification of antibodies using Protein A affinity chromatography
MX2012004711A (es) Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
PH12015501848A1 (en) Binding agents
MY174493A (en) Binding agents
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MX348178B (es) Método para purificar adamts13 recombinante y otras proteínas y sus composiciones.
UA92505C2 (ru) Композиции на основе антитела против cd3
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
TW200716646A (en) (S)-N-methylnaltrexone
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
WO2011047087A3 (en) Protein detection via nanoreporters
WO2010129304A3 (en) Method for making heteromultimeric molecules
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
WO2012024400A3 (en) Elution of proteins from hydroxyapatite resins without resin deterioration
MX2010001723A (es) Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2008051448A3 (en) Methods and compositions for efficient removal of protein a from binding molecule preparations
EP1896588A4 (en) NOVEL Aβ BINDING PROTEIN, ITS PEPTIDE DERIVATIVES AND USES THEREOF
MX2015005579A (es) Metodo para aislar synagis(r) en ausencia de benzonasa.
MX2021016092A (es) Metodos de purificacion de proteinas.
WO2006078581A3 (en) Inactivated pepsin fraction, pharmaceutical compositions, and methods for detecting and treating diseases